CAR T-cell Dosage Control Reducing Neurotoxicity Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell therapy methods, particularly those involving T cell compositions with recombinant receptors like CARs, face challenges in reducing toxicity while maintaining efficacy, with severe toxicities such as neurotoxicity being a significant concern.
Innovation Solution
The development of therapeutic T cell compositions and methods that include a unit dose of T cells with specific receptor activity, where the dose is calculated based on the number of cells and their activity level, using a formula to define reference units, and incorporating instructions for administration to minimize toxicity risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a higher number of T cells with recombinant receptors are administered to maintain therapeutic efficacy, then the treatment effectiveness is improved, but the risk of severe toxicities such as neurotoxicity increases
Solution Approach 1:
The patent applies parameter changes by establishing specific dosage ranges (e.g., 1×10^6 to 1×10^8 T cells per kilogram of body weight) and defining reference units based on cellular activity metrics. This quantitative standardization transforms the treatment from qualitative to precise parameter-based dosing, enabling optimization of both efficacy and safety by selecting appropriate dosage levels within the defined ranges.
Solution Approach 2:
The patent implements feedback mechanisms through monitoring protocols that assess patient response and toxicity markers after T cell administration. This feedback enables adjustment of subsequent dosing strategies, allowing the treatment to be optimized based on actual patient outcomes while managing toxicity risks through data-driven decision making.
2Power
If the dosage of T cell composition is increased to ensure sufficient therapeutic effect, then the treatment potency is improved, but the control over toxicity becomes more difficult
Solution Approach 1:
The patent segments the T cell population into distinct subsets based on their functional characteristics and receptor expression levels. By defining reference units for different cell phenotypes (e.g., memory phenotype vs. effector phenotype), the patent enables precise control over the composition and potency of the administered product, allowing tailored dosing that balances therapeutic effect with toxicity management.
Solution Approach 2:
The patent establishes multiple dosage parameters including total cell count, cell viability percentage, and reference unit concentrations. These segmented parameters provide granular control over treatment potency while enabling independent optimization of each parameter to achieve desired therapeutic outcomes with minimized toxicity risks.
3Ease of operation
If standard dosing protocols are used without considering individual patient factors, then the administration process is simplified, but the risk of adverse events increases
Solution Approach 1:
The patent applies local quality by tailoring the T cell dosage to individual patient characteristics such as body weight, disease burden, and immune system status. Instead of universal dosing, the treatment is customized to each patient's specific needs and risk factors, thereby maintaining administrative feasibility while significantly improving safety and efficacy outcomes through personalized medicine approaches.
Data Source
AI summary
Provided herein are methods, compositions and articles of manufacture for use in connection with cell therapy involving the administration of one or more doses of a therapeutic T cell composition. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the provided embodiments, including the numbers of cells or units of cells administered and/or the potency of administered cells, provide various advantages, such as lower risk of toxicity in subjects administered the T cell compositions.